Welcome to our dedicated page for Tenaya Therapeutics news (Ticker: TNYA), a resource for investors and traders seeking the latest updates and insights on Tenaya Therapeutics stock.
Tenaya Therapeutics, Inc. (NASDAQ: TNYA) is a clinical-stage biotechnology company focused on discovering, developing and delivering potentially curative therapies that address the underlying drivers of heart disease. The Tenaya Therapeutics news feed highlights company announcements, clinical data updates and financial disclosures related to its gene therapy and small molecule programs for genetic cardiomyopathies and heart failure.
News about Tenaya frequently centers on TN-201, its AAV9-based gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM), and TN-401, its AAV9-based gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC). Company press releases provide interim safety, biopsy and early efficacy results from the MyPEAK-1 and RIDGE-1 Phase 1b/2 clinical trials, including observations on protein expression, arrhythmia measures and biomarkers.
Investors and followers of TNYA can also find updates on regulatory interactions, such as FDA designations and clinical hold communications, as well as information on Tenaya’s capital-raising activities through public offerings described in SEC filings and related press releases. Additional news items cover participation in scientific and investor conferences, late-breaking presentations at major cardiology and gene therapy meetings, and publications that describe Tenaya’s research platforms and preclinical findings.
This page aggregates these disclosures so readers can review Tenaya Therapeutics’ latest reported milestones, from clinical trial progress for TN-201 and TN-401 to developments in its broader pipeline, including the TN-301 small molecule HDAC6 inhibitor and early-stage preclinical programs. For those tracking TNYA, the news stream offers a consolidated view of how the company reports advancing its mission to address genetic drivers of heart disease.
Tenaya Therapeutics (Nasdaq: TNYA) has announced the pricing of a public offering of 75,000,000 units at $0.70 per unit, aiming to raise gross proceeds of approximately $52.5 million before deducting underwriting costs and expenses.
Each unit consists of one common stock share, a Series A Warrant (exercise price $0.80, 5-year expiration), and a Series B Warrant (exercise price $0.70, expires June 30, 2026) to purchase half a share. The offering is expected to close around March 5, 2025.
The clinical-stage biotech company plans to use the net proceeds to fund ongoing and planned development of clinical and early-stage product candidates, particularly TN-201 and TN-401, along with working capital and general corporate purposes. Leerink Partners and Piper Sandler are serving as joint book-running managers for the offering.
Tenaya Therapeutics (Nasdaq: TNYA), a clinical-stage biotechnology company focused on heart disease therapies, has announced plans for a proposed public offering. The offering will consist of units comprising common stock and two series of warrants (Series A and Series B) to purchase common stock.
The company will also offer pre-funded units to certain investors, which include pre-funded warrants priced at $0.001 per share, along with Series A and Series B warrants. The pre-funded warrants will be immediately exercisable with no expiration date.
Leerink Partners and Piper Sandler are serving as joint bookrunning managers for the offering. The securities will be offered through a previously filed and SEC-approved Registration Statement on Form S-3. The completion, size, and terms of the offering remain subject to market conditions.
Tenaya Therapeutics (NASDAQ: TNYA), a clinical-stage biotechnology company focused on developing curative therapies for heart disease, has announced its participation in two major investor conferences in March 2025.
The company will be featured at:
- TD Cowen's 45th Annual Health Care Conference on Tuesday, March 4, with a company presentation from 1:10 PM ET to 1:40 PM ET
- Leerink Partners Global Healthcare Conference 2025 on Wednesday, March 12, participating in a fireside chat from 8:40 AM ET to 9:10 AM ET
CEO Faraz Ali will represent the company at both events. Live and archived webcasts will be available through Tenaya's website Investors section, with replays accessible for approximately 30 days after each conference.
Tenaya Therapeutics (NASDAQ: TNYA) has received an $8 million CLIN2 grant from the California Institute for Regenerative Medicine (CIRM) to support its ongoing RIDGE-1 Phase 1b clinical trial of TN-401 gene therapy. The therapy is being developed to treat PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC), a severe progressive disease affecting approximately 70,000 people in the U.S.
TN-401 is designed as a one-time intravenous gene replacement therapy using AAV9 capsid to deliver functional PKP2 genes into heart muscle cells, addressing the underlying cause of the disease. The RIDGE-1 trial is currently enrolling symptomatic adults with PKP2-associated ARVC, with initial data from the low-dose cohort expected in the second half of 2025.
Tenaya Therapeutics (NASDAQ: TNYA) has outlined its strategic priorities for 2025, focusing on advancing its gene therapy programs. The company has initiated dosing in Cohort 2 of the MyPEAK-1 Phase 1b/2 clinical trial of TN-201 for MYBPC3-Associated Hypertrophic Cardiomyopathy, with additional Cohort 1 data expected in 1H25.
Initial data from Cohort 1 showed TN-201 was generally well-tolerated at 3E13 vg/kg dose, with detectable vector DNA and transgene RNA expression in the first two patients. The company plans to complete Cohort 2 enrollment in 1H25 and provide initial data in 2H25.
For the TN-401 program targeting PKP2-Associated ARVC, Tenaya expects to complete Cohort 1 enrollment in 1H25 and report initial clinical data in 2H25. The company also plans to activate its first ex-U.S. RIDGE-1 clinical site in 1H25.
Tenaya Therapeutics (NASDAQ: TNYA) has reported promising early data from the first cohort of the MyPEAK-1 Phase 1b/2 clinical trial of TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM). The trial's preliminary results from three patients at the 3E13 vg/kg dose showed that TN-201 was generally well-tolerated with:
- Detectable vector DNA in the heart
- Evidence of transgene RNA expression
- Increasing TN-201 mRNA and MyBP-C protein levels over time
- Stable or improved circulating biomarkers of cardiac muscle strain and injury
The first patient reached 52 weeks, the second 40 weeks, and the third 12 weeks of follow-up. Additional data readouts from Cohort 1 and the higher dose Cohort 2 are expected in 2025.
Tenaya Therapeutics (NASDAQ: TNYA) announced it will present initial data from Cohort 1 of the MyPEAK-1 Phase 1b/2 clinical trial of TN-201 gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM) on December 17, 2024. The company will host a conference call and webcast at 8:00 a.m. ET to discuss the results. The presentation will be accessible through the company's website, with a replay available afterward in the Investor Relations section.
Tenaya Therapeutics (NASDAQ: TNYA) has dosed the first patient in its RIDGE-1 Phase 1b clinical trial of TN-401, a gene therapy treatment for PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC). The trial, currently enrolling at six U.S. centers, will assess safety and efficacy of a one-time intravenous infusion in up to fifteen adults with PKP2-associated ARVC. TN-401 uses AAV9 capsid to deliver functional PKP2 genes to heart cells, aiming to address the underlying cause of the disease. Initial clinical data is expected in 2025. The first dose being tested is 3E13 vg/kg, which showed near maximal efficacy in preclinical studies.
Tenaya Therapeutics (NASDAQ: TNYA) has granted stock options to two new non-executive employees as employment inducements. The options allow purchase of 12,000 total shares at $1.97 per share, matching the November 15, 2024 closing price. These ten-year options vest over four years, with 25% vesting after one year and the remainder vesting monthly at 1/48th of the original shares. The grants were made under the company's 2024 Inducement Equity Incentive Plan in accordance with NASDAQ Rule 5635(c)(4).
Tenaya Therapeutics (NASDAQ: TNYA) reported Q3 2024 financial results and provided updates on its gene therapy programs. The company completed dosing of the first three patients in Cohort 1 of the MyPEAK-1 trial for TN-201, with the Data Safety Monitoring Board endorsing dose escalation to Cohort 2. Initial data from Cohort 1 will be reported in December 2024. The company reported a net loss of $25.6 million ($0.30 per share) and had cash and investments of $79.5 million as of September 30, 2024, sufficient to fund operations into second half of 2025. R&D expenses were $20.4 million, down from $23.1 million in Q3 2023.